Date: 2012-11-12
Type of information: Production agreement
Compound: Busulipo™ (busulfan)
Company: Pharmalink (Sweden) GP Pharm (Spain)
Therapeutic area: Transplantation
Type agreement: manufacturing
production
Action mechanism: Busulipo™ is a conditioning agent for use prior to hematopoietic stem cell transplantation (HSCT)
Disease:
Details: Pharmalink AB, a Swedish specialty pharma company, has entered into a contract with GP Pharm for the manufacturing of Pharmalink’s Busulipo™, which is under development to provide a best-in-class conditioning agent for use prior to hematopoietic stem cell transplantation. The agreement covers the manufacturing of Busulipo™ from clinical to commercial quantities and is an important step in progressing the product towards the market. No commercial terms were disclosed.
Financial terms:
Latest news:
